Completely resected NSCLC (stage IB - IIIA including multiple N2)
Conditions
Interventions
Period: From March 2011 to Febrary 2013 Dose:GEM 1000mg/m2 d1.d8+CDDP 80mg/m2 d1 Cycle: 4 cycles
Sponsors
Kumamoto University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)The patient histologically proven as non-small cell lung cancer (2)The patient with p-staged IB - IIIA that received segmentectomy, lobectomy, or bi-lobectomy (including multiple pN2) (3) Performance Status is 0 - 1 (ECOG). (4) 20 years of age or older, 80 years of age or younger. (5) The patient who does not receive any chemotherapy, radiotherapy, or immunotherapy prior to resection (6) The patient who preserves the main organ ( the bone marrow, liver, kidney and so on ) (7) The patient who can receive chemotherapy within 4 - 12 weeks after resection (8) The patient who gives written informed consent
Exclusion criteria
Exclusion criteria: (1)The patient with infection (2)The patient with fever (equal to or more than 38 C) (3)The patient with heavy complication (4)The patient with active double-cancer (5)The patient with chickenpox (6)The patient with a motor-palsy or figure of peripheral-nerve-disease (7)The patient with drug hypersensitivity (8)The expectant mother, the woman who has a lactating-woman and the possibility of the pregnancy (9)The patient judged as unsuitable by the doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chemotherapy compliance in the four cycles | — |
Countries
Japan
Contacts
Public ContactMakoto Suzuki
Kumamoto University Hospital Department of Thoracic Surgery
Outcome results
None listed